

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**The Securities and Exchange Act of 1934**

Date of Report (Date of earliest event reported) : September 3, 2009

---

**IntelGenx Technologies Corp.**  
(Exact Name of Registrant as Specified in Charter)

---

**Delaware**

(State or other jurisdiction  
of incorporation)

**000-31187**

(Commission File No.)

**87-0638336**

(IRS Employer ID)

---

**6425 Abrams, Ville Saint Laurent, Quebec, H4S 1X9 Canada**

(Address of principal executive offices and Zip Code)

---

**(514) 331-7440**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- £ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - £ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

### Item 3.02 Unregistered Sales of Equity Securities

On September 3, 2009, IntelGenx Technologies Corp. (the "Company") completed an offering of 250,000 units (the "Units") at CDN\$0.41 per Unit for gross proceeds of CDN\$102,500 ("the "Offering"), pursuant to the terms of subscription agreement with its investor (the "Subscription Agreement"). Each Unit consists of one common share of the Company (a "Unit Share") and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to purchase one common share of the Company (a "Warrant Share") at an initial exercise price of US\$0.80 per common share and expires on September 3, 2012. The exercise price of the Warrants is subject to adjustment for certain events, including without limitation, dividends, distributions or split of the Company's common stock, subsequent rights offerings by the Company, or in the event of the Company's consolidation, merger or reorganization.

The foregoing issuances were exempt from registration under Section 4(2) of the Securities Act of 1933, as amended (the "Act"). The Unit Shares, the Warrants and the Warrant Shares are subject to statutory resale restrictions under the Act and contain, or will contain upon issuance, a legend restricting the sale of such securities in accordance with applicable exemptions from the registration requirements of the Act. Pursuant to the Subscription Agreements, there are no registrations right provided for this offering.

### Item 9.01 Financial Statements and Exhibits

#### (c) Exhibits

Exhibit Number	Description
----------------	-------------

99.1	IntelGenx Technologies Corp. completes additional Private Placement
------	---

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### INTELGENX TECHNOLOGIES CORP.

By: /s/ Horst Zerbe  
Horst G. Zerbe  
President and Chief Executive Officer

Date: September 4, 2009

## IntelGenx Technologies Corp. completes additional Private Placement

Saint Laurent, Québec, Canada - September 4, 2009) - IntelGenx Technologies Corp. (the "Company") (TSX-V:IGX; OTC-BB: IGXT) announced today that it has completed the sale of 250,000 units ("Units") at a price of Cdn \$0.41 per unit for gross proceeds of Cdn \$102,500.00 (the "Offering"). Each Unit comprises one common share ("Common Share") of the Company and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at a price of US \$0.80 ("Exercise Price") until September 3, 2012. The Company issued and sold approximately 10.5 million Special Warrants under its previously announced private placement offering for Cdn \$0.40 per Special Warrant for gross proceeds of approximately Cdn \$4.2 million on July 13, 2009.

The Units, the underlying Common Shares and Warrants as well as the Common Shares underlying the Warrants are subject to statutory resale restrictions under applicable securities laws in Canada until January 3, 2010. The securities have not been registered under the U.S. Securities Act and may not be offered or sold absent registration under the U.S. Securities Act or an applicable exemption from the registration requirements thereof. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

### ABOUT INTELGENX TECHNOLOGIES CORP.

IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. Intelgenx's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis and depressive disorders. More information is available about the company at [www.intelgenx.com](http://www.intelgenx.com)

### CONTACT INFORMATION

IntelGenx Technologies Corp.  
Dr. Horst G. Zerbe, President and CEO  
T: 514-331-7440 (ext. 201)  
F: 514-331-0436  
[horst@intelgenx.com](mailto:horst@intelgenx.com)  
[www.intelgenx.com](http://www.intelgenx.com)

The TSX Venture Exchange and OTC Bulletin Board have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

---